STENOCARE 3.0 Strategy: Management Shares Insights in Exclusive Interview with Proinvestor.com
STENOCARE A/S
NASDAQ FIRST NORTH GROWTH MARKET, DENMARK
TICKER: STENO
Stenocare has announced its STENOCARE 3.0 strategy, unveiled on November 26, which marks a bold new chapter in its mission to become a leader in the medical cannabis industry. This transformative strategy positions Stenocare as a specialised Trading Company, focused on delivering high-quality, prescription-based medical cannabis products to carefully selected markets. By leveraging innovation and global partnerships, Stenocare aims to create superior value for patients and stakeholders.
The management team recently shared their insights into this strategic shift in an interview with ProInvestor.com, now available on the Stenocare Facebook page and the Proinvestor website:
- With English subtitles: STENOCARE Facebook: https://www.facebook.com/stenocare
- In Danish without subtitles: Proinvestor.com: https://proinvestor.com/boards/123352/
At the heart of the strategy is the revolutionary ASTRUM 10-10 oil product, which has been approved for sale in Australia, Germany, and Norway. This patented product offers a significant competitive edge by improving bioavailability, ensuring greater predictability in dosage delivery for patients. Stenocare holds the exclusive global rights to this breakthrough technology in the medical cannabis space.
In addition to product innovation, Stenocare has established a strong international presence, with valuable assets in 6 countries and 13 products approved for sale by local health authorities. The company's proven logistical and distribution model ensures high-quality products reach patients efficiently across Europe and Australia.
“Our STENOCARE 3.0 strategy is a game-changer,” said Thomas Skovlund Schnegelsberg, CEO of Stenocare. “By focusing on innovation and strategic partnerships, we are not only strengthening our competitive position but also enhancing our ability to serve patients with reliable and high-quality medical cannabis products.”
With ambitious plans to grow sales and expand market share, Stenocare is poised to lead the way in a rapidly evolving industry.